| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T484 |
86-254 |
Sentence |
denotes |
Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2. |
| T485 |
255-331 |
Sentence |
denotes |
In a Phase I clinical testing up 14 days dosing, ORE1001 was well tolerated. |
| T486 |
332-416 |
Sentence |
denotes |
Subjects received drug (dosing up to 2100 mg) with no side adverse effects reported. |
| T487 |
417-554 |
Sentence |
denotes |
In particular, 47 subjects received single-dose from 2.1 to 2100 mg and 24 subjects received 14 day multiple doses from 50 mg to 1800 mg. |
| T488 |
555-644 |
Sentence |
denotes |
All doses were well tolerated, with no significant side effects including blood pressure. |
| T489 |
645-802 |
Sentence |
denotes |
Pharmacokinetics of orally administered capsules was consistent with once-daily dosing. (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf). |
| T490 |
803-961 |
Sentence |
denotes |
300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597). |
